Design Therapeutics, Inc. Share Price & Technical Analysis
DSGN · $10.97 (-0.36%)
Healthcare / Biotechnology
$10.97
-0.36%
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentia…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-19% return in May, -7% avg return in past 3 year May month.
23% return in 2026, 40% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | 3% | 4% | 27% | -19% | – | – | – | – | – | – | – | 23% |
| 25 | -23% | 4% | -20% | 29% | -24% | -11% | 15% | 45% | 36% | -11% | 40% | 1% | 82% |
| 24 | -11% | 17% | 43% | -12% | 17% | -20% | 55% | -6% | 13% | -4% | 13% | 3% | 108% |
| 23 | -24% | -9% | -17% | 10% | -14% | 13% | 29% | -69% | -4% | -17% | 20% | 13% | -70% |
| 22 | -41% | 6% | 18% | -26% | 0% | 12% | 40% | 4% | -16% | -8% | -12% | -26% | -50% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$968.08M
P/E ratio
—
52W high
$17.25
52W low
$3.33
Volume
10,06,095
Beta
1.74
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Design Therapeutics, Inc. share price today?
- Design Therapeutics, Inc. (DSGN) last traded around $10.97 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DSGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DSGN. Download the app for real-time alerts.
- How can I analyze Design Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.